$HSDT
HELIUS MEDICAL TECHNOLOGIES, INC.

2020 Form 10-K Financial Statement

#000156459021012121 Filed on March 10, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $661.0K $150.0K $500.0K
YoY Change 32.2% -68.75% 4.6%
Cost Of Revenue $388.0K $310.0K $850.0K
YoY Change -54.35%
Gross Profit $273.0K -$160.0K $650.0K
YoY Change -58.0% -133.33% 35.42%
Gross Profit Margin 41.3% -106.67% 130.0%
Selling, General & Admin $9.714M $3.810M $16.52M
YoY Change -41.2% 6.42% -4.0%
% of Gross Profit 3558.24% 2541.69%
Research & Development $4.582M $1.600M $8.061M
YoY Change -43.16% -25.93% -18.9%
% of Gross Profit 1678.39% 1240.15%
Depreciation & Amortization $119.0K $100.0K $127.0K
YoY Change -6.3% 400.0% 115.25%
% of Gross Profit 43.59% 19.54%
Operating Expenses $14.66M $5.470M $24.65M
YoY Change -40.52% -4.7% -9.23%
Operating Profit -$14.39M -$5.630M -$24.00M
YoY Change -40.05% 7.03% -10.04%
Interest Expense $193.0K $230.0K $14.12M
YoY Change -98.63% 53.33% -802.49%
% of Operating Profit
Other Income/Expense, Net $63.00K $60.00K $14.22M
YoY Change -99.56% -829.72%
Pretax Income -$14.13M -$5.330M $9.781M
YoY Change -244.46% 4.1% -65.83%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$14.13M -$5.330M -$9.781M
YoY Change 44.46% 4.1% -65.83%
Net Earnings / Revenue -2137.67% -3553.33% -1956.2%
Basic Earnings Per Share -$11.80 -$12.99
Diluted Earnings Per Share -$11.80 -$6.747M -$12.99
COMMON SHARES
Basic Shares Outstanding 1.198M 752.9K
Diluted Shares Outstanding 1.198M 752.9K

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.331M $5.460M $5.460M
YoY Change -38.99% -78.66% -78.66%
Cash & Equivalents $5.459M
Short-Term Investments
Other Short-Term Assets $735.0K $610.0K $610.0K
YoY Change 20.49% 131.06% -14.08%
Inventory $389.0K $598.0K $600.0K
Prepaid Expenses $610.0K
Receivables $74.00K $210.0K $210.0K
Other Receivables $156.0K $364.0K $360.0K
Total Short-Term Assets $4.685M $7.241M $7.240M
YoY Change -35.29% -73.14% -73.15%
LONG-TERM ASSETS
Property, Plant & Equipment $576.0K $712.0K $1.260M
YoY Change -54.29% 28.52% 129.09%
Goodwill $1.242M
YoY Change
Intangibles $582.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $18.00K $20.00K
YoY Change -100.0% 0.0% 0.0%
Total Long-Term Assets $1.862M $3.106M $3.110M
YoY Change -40.13% 258.66% 257.47%
TOTAL ASSETS
Total Short-Term Assets $4.685M $7.241M $7.240M
Total Long-Term Assets $1.862M $3.106M $3.110M
Total Assets $6.547M $10.35M $10.35M
YoY Change -36.74% -62.82% -62.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $747.0K $1.676M $1.680M
YoY Change -55.54% -29.93% -29.71%
Accrued Expenses $1.396M $1.519M $1.690M
YoY Change -17.4% -16.17% -6.63%
Deferred Revenue $430.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.424M $3.802M $3.800M
YoY Change -36.21% -78.85% -78.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $252.0K $710.0K $710.0K
YoY Change -64.51%
Total Long-Term Liabilities $252.0K $710.0K $710.0K
YoY Change -64.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.424M $3.802M $3.800M
Total Long-Term Liabilities $252.0K $710.0K $710.0K
Total Liabilities $2.676M $4.512M $4.510M
YoY Change -40.67% -74.9% -74.9%
SHAREHOLDERS EQUITY
Retained Earnings -$104.8M
YoY Change 10.3%
Common Stock $111.5M
YoY Change 5.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.871M $5.835M $5.840M
YoY Change
Total Liabilities & Shareholders Equity $6.547M $10.35M $10.35M
YoY Change -36.74% -62.82% -62.81%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$14.13M -$5.330M -$9.781M
YoY Change 44.46% 4.1% -65.83%
Depreciation, Depletion And Amortization $119.0K $100.0K $127.0K
YoY Change -6.3% 400.0% 115.25%
Cash From Operating Activities -$11.74M -$4.540M -$21.00M
YoY Change -44.1% -11.67% 7.02%
INVESTING ACTIVITIES
Capital Expenditures $63.00K -$90.00K $278.0K
YoY Change -77.34% 800.0% -36.82%
Acquisitions $416.0K
YoY Change
Other Investing Activities $61.00K -$420.0K -$420.0K
YoY Change -114.52%
Cash From Investing Activities -$9.000K -$510.0K -$769.0K
YoY Change -98.83% 5000.0% 74.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.65M $1.685M
YoY Change 532.23% -95.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.638M 1.490M 1.653M
YoY Change 483.06% -91.88% -95.87%
NET CHANGE
Cash From Operating Activities -11.74M -4.540M -21.00M
Cash From Investing Activities -9.000K -510.0K -769.0K
Cash From Financing Activities 9.638M 1.490M 1.653M
Net Change In Cash -2.128M -3.560M -20.12M
YoY Change -89.43% -126.99% -200.51%
FREE CASH FLOW
Cash From Operating Activities -$11.74M -$4.540M -$21.00M
Capital Expenditures $63.00K -$90.00K $278.0K
Free Cash Flow -$11.80M -$4.450M -$21.28M
YoY Change -44.54% -13.26% 6.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2019 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q4 hsdt Number Of Operating Lease
NumberOfOperatingLease
1
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1197774
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020 us-gaap Gross Profit
GrossProfit
273000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
877672
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
64000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5835000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
877672
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10347000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019 us-gaap Gross Profit
GrossProfit
650000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4582000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8061000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9714000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16521000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
363000
CY2020 us-gaap Operating Expenses
OperatingExpenses
14659000
CY2019 us-gaap Operating Expenses
OperatingExpenses
24646000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-14386000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-23996000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
63000
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-38445
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4787690
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
642 Newtown Yardley Road, Suite 100
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Newtown
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18940
CY2020 dei City Area Code
CityAreaCode
(215)
CY2020 dei Local Phone Number
LocalPhoneNumber
944-6100
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2311099
CY2020Q2 dei Entity Public Float
EntityPublicFloat
17405309
CY2020Q4 us-gaap Cash
Cash
3331000
CY2019Q4 us-gaap Cash
Cash
5459000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
74000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
210000
CY2020Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
156000
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
364000
CY2020Q4 us-gaap Inventory Net
InventoryNet
389000
CY2019Q4 us-gaap Inventory Net
InventoryNet
598000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
735000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
610000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
7241000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
712000
CY2020Q4 us-gaap Goodwill
Goodwill
759000
CY2019Q4 us-gaap Goodwill
Goodwill
1242000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
527000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
582000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2019Q4 us-gaap Other Assets
OtherAssets
2394000
CY2019Q4 us-gaap Assets
Assets
10347000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1676000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1519000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
95000
CY2020 hsdt Foreign Currency Transaction Including Other Gain Loss Before Tax
ForeignCurrencyTransactionIncludingOtherGainLossBeforeTax
189000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-197000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-311000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14327000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10092000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.80
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.99
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.80
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.99
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1197774
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
752932
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1197774
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
752932
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
9854000
CY2019 hsdt Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
215000
CY2019 hsdt Adjustments To Additional Paid In Capital Reclassification Of Derivative Financial Instruments From Exercise Of Warrants
AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivativeFinancialInstrumentsFromExerciseOfWarrants
35000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4691000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-311000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
819000
CY2020 us-gaap Profit Loss
ProfitLoss
-14130000
CY2019 us-gaap Profit Loss
ProfitLoss
-9781000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2529000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
4691000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
182000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-70000
CY2020 us-gaap Depreciation
Depreciation
119000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
247000
CY2019 hsdt Proceeds From Exercise Of Warrants And Stock Options
ProceedsFromExerciseOfWarrantsAndStockOptions
215000
CY2020 hsdt Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
323000
CY2020 hsdt Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
323000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9638000
CY2020 us-gaap Adjustment For Amortization
AdjustmentForAmortization
363000
CY2019 us-gaap Adjustment For Amortization
AdjustmentForAmortization
64000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
140000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
220000
CY2020 hsdt Provision For Inventory Reserve
ProvisionForInventoryReserve
205000
CY2019 hsdt Provision For Inventory Reserve
ProvisionForInventoryReserve
50000
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
184000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-110000
CY2020 hsdt Gain Loss On Lease Modification
GainLossOnLeaseModification
56000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
438000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-226000
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
278000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
256000
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
125000
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
163000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-264000
CY2020 hsdt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-28000
CY2019 hsdt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-13000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-635000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1116000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-280000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-327000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-174000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11738000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20999000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
278000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
61000
CY2019 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
416000
CY2020 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
7000
CY2019 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
75000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-769000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10653000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1685000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1015000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1653000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-19000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-9000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2128000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20124000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5459000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25583000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3331000
CY2020 hsdt Share Issuance Costs Included In Accounts Payable And Accrued Liabilities
ShareIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
162000
CY2019 hsdt Share Issuance Costs Included In Accounts Payable And Accrued Liabilities
ShareIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
358000
CY2019 hsdt Reclassification Of Derivative Instruments From Warrant Exercise
ReclassificationOfDerivativeInstrumentsFromWarrantExercise
35000
CY2019 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
1227000
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="N1_DESCRIPTION_BUSINESS_BASIS_PRESENTATI"></a><a name="N1_DESCRIPTION_BUSINESS_BASIS_PRESENTATI"></a>DESCRIPTION OF BUSINESS</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Helius Medical Technologies, Inc. (the &#8220;Company&#8221;), is neurotech company focused on neurological wellness. The Company&#8217;s purpose is to develop, license or acquire unique and non-invasive technologies targeted at reducing symptoms of neurological disease or trauma.</font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s first product, known as the Portable Neuromodulation Stimulator (&#8220;PoNS<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup><font style="font-family:Calibri;">&#8221;)</font>, <font style="Background-color:#FFFFFF;">is authorized for sale in Canada as a class II, non-implantable medical device intended for use as a short term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (&#8220;MS&#8221;,) and balance deficit due to mild-to-moderate traumatic brain injury (&#8220;mmTBI&#8221;) and is to be used in conjunction with supervised therapeutic exercise (&#8220;PoNS Treatment<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>&#8221;). It is an investigational medical device in the United States, the European Union (&#8220;EU&#8221;), and Australia (&#8220;AUS&#8221;). The device is currently under review for de novo classification and clearance by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) as a potential treatment for gait deficit due to symptoms of MS. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS Treatment&#8482; is not currently commercially available in the United States, the European Union or Australia.</font>&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated in British Columbia, Canada, on March 13, 2014. On May 28, 2014, the Company completed a continuation via a plan of arrangement whereby the Company moved from being a corporation governed by the British Columbia Corporations Act to a corporation governed by the Wyoming Business Corporations Act. On July 20, 2018, the Company completed its reincorporation from Wyoming to the state of Delaware. The Company is headquartered in Newtown, Pennsylvania. <font style="Background-color:#FFFFFF;color:#000000;"> On December 21, 2018, the Company&#8217;s wholly owned subsidiary, NeuroHabilitation Corporation, changed its name to Helius Medical, Inc (&#8220;HMI&#8221;). On January 31, 2019, the Company formed another wholly owned subsidiary, Helius NeuroRehab, Inc., (&#8220;HNR&#8221;), a Delaware corporation. On October 10, 2019, the Company formed Helius Canada Acquisition Ltd. (&#8220;HCA&#8221;), a company incorporated under the federal laws of Canada and a wholly owned subsidiary of Helius Medical Technologies (Canada), Inc. (&#8220;HMC&#8221;), a company incorporated under the federal laws of Canada, which acquired Heuro Canada, Inc. (&#8220;Heuro&#8221;) from Health Tech Connex Inc. (&#8220;HTC&#8221;) on October 30, 2019. </font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s wholly owned subsidiaries are comprised of HMI, HMC, HCA and HNR.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Class A common stock, par value $0.001 per share (&#8220;common stock&#8221;) is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) and the Toronto Stock Exchange (the &#8220;TSX&#8221;). The common stock began trading on the Canadian Securities Exchange on June 23, 2014, under the ticker symbol &#8220;HSM&#8221; and the trading was subsequently transferred to the TSX on April 18, 2016. On April 11, 2018, the common stock began trading on Nasdaq under the ticker symbol &#8220;HSDT&#8221; after having traded on the OTCQB in the United States under the ticker symbol &#8220;HSDT&#8221; since February 10, 2015. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Reverse Stock Split</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective after the close of business on December 31, 2020, the Company completed a 1-for-35 reverse stock split of its common stock. <font style="font-family:TimesNewRomanPSMT;color:#000000;">All share and per share amounts in this Annual Report have been reflected on a post-split basis.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Going Concern Uncertainty</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had cash of $3.3 million. For the year ended December&#160;31, 2020, the Company incurred a net loss of $14.1 million and, as of December&#160;31, 2020, its accumulated deficit was $118.9 million. For the year ended December&#160;31, 2020, the Company had $0.7 million of revenue from the commercial sale of products or services. The Company expects to continue to incur operating losses and net cash outflows until it generates a level of revenue to support its cost structure. There is no assurance that the Company will achieve profitable operations, and, if achieved, whether it will be sustained on a continued basis. These factors indicate<font style="Background-color:#FFFFFF;color:#000000;"> substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are filed.&#160;&#160;The Company&#8217;s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business; no adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company intends to fund ongoing activities by utilizing its current cash on hand, cash received from the sale of its PoNS device in Canada and by raising additional capital through equity or debt financings. As discussed further in Note 10, in January 2021, the Company received $1.3 million in net proceeds from the exercise of warrants issued in the March 2020 registered direct offering and on February 1, 2021, closed a public offering and received net proceeds of approximately $9.6 million. There can be no assurance that the Company will be successful in raising that additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditures.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks and Uncertainties</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (&#8220;COVID-19&#8221;) as a global pandemic, which continues to spread throughout the United States and around the world. The Company&#8217;s business, results of operations and financial condition have been and may continue to be adversely impacted by the COVID-19 pandemic and global economic conditions. The outbreak and spread of COVID-19 has significantly increased economic uncertainty.&nbsp;&nbsp;Authorities implemented numerous measures to try to contain COVID-19, such as travel bans and restrictions, quarantines, shelter in place orders, and business shutdowns.&nbsp;&nbsp;The COVID-19 pandemic initially led to the closure of PoNS Authorized clinic locations across Canada. While all clinics have re-opened, they are all currently operating at reduced capacity, and patients have been and may continue to be less willing to return to these clinics, impacting our commercial activities and our customer engagement efforts. Moreover, the Company&#8217;s ability to conduct its ongoing clinical experience programs in Canada has been and may continue to be impaired due to trial participants&#8217; attendance being adversely affected by COVID-19, leading to further delays in the development and approval of the Company&#8217;s product candidate. In addition, the COVID-19 pandemic has and may continue to cause delays in the Company&#8217;s suppliers&#8217; ability to ship materials that the Company relies upon, and disruptions in business or governmental operations due to COVID-19 may delay the timing for the submission and approval of the Company&#8217;s marketing applications with regulatory agencies. Further, the economic impact of the COVID-19 pandemic could affect the Company&#8217;s ability to access the public markets and obtain necessary capital in order to properly capitalize and continue its operations. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which the COVID-19 pandemic will continue to impact the Company&#8217;s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted.&nbsp;&nbsp;The Company does not know yet the full extent of the impact of COVID-19 on its future business, operations or the global economy as a whole.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Nasdaq Delisting</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 23, 2020, the Company received notice from the Staff of Nasdaq that the bid price for the Company&#8217;s common stock had closed below $1.00 per share for the prior 30 consecutive business day period and that the Company had been granted a 180-day grace period, through September 21, 2020, to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;). Thereafter, on April 17, 2020, the Company received an additional notice from the Staff indicating that Nasdaq had temporarily stayed enforcement of the Minimum Bid Price Rule through June 30, 2020, and accordingly, the 180-day grace period applicable to the Company would not expire until December 3, 2020.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 4, 2020, the Company received notice from the Staff indicating that the Company was not eligible for an additional 180-day extension to meet the Minimum Bid Price Rule. As a result, the Staff determined that the Company&#8217;s securities would be subject to delisting unless the Company timely requested a hearing before the Panel. The Company timely submitted a request for a hearing before the Panel, which request stayed any suspension or delisting action by Nasdaq at least until the hearing process concluded and any extension granted by the Panel expired. On January 15, 2021, the Company received notice from the Staff that the bid price deficiency of the Company had been cured, and that the Company was in compliance with all applicable listing standards, and so the scheduled hearing before the Panel was cancelled.</p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosure of contingent assets and liabilities. Significant estimates include the assumptions used in the valuation of the fair value-pricing model for stock-based compensation, derivative financial instruments and deferred income tax asset valuation allowance. Financial statements include estimates, which, by their nature, are uncertain. Actual results could differ from those estimates.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk with respect to its cash. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company is not currently exposed to any significant concentrations of credit risk from these financial instruments. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return.</p>
CY2019 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
16000
CY2020 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
503000
CY2020 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-03-13
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-35
CY2020 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
35
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
400000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
200000
CY2020Q4 hsdt Rent Deposits Receivable
RentDepositsReceivable
18000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
200000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
205000
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
50000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
160000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
144000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
440000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
375000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
44000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
129000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
644000
CY2019Q4 us-gaap Inventory Gross
InventoryGross
648000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
255000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
50000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
689000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
897000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
203000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
185000
CY2020 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
400000
CY2020Q4 hsdt Business Acquisition Purchase Price Allocation Goodwill Not Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillNotExpectedTaxDeductibleAmount
700000
CY2019 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-1226000
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
20000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
972000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-445000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
646000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-64000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
197000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
183000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
122000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
25000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
527000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2020Q4 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-11.80
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.99
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
455631
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
752932
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
186764
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1801000
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2020 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q4 hsdt Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
2025
CY2020Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
900000
CY2019Q4 hsdt Fair Value Of Warrants Liability
FairValueOfWarrantsLiability
5000
CY2018Q4 hsdt Fair Value Of Warrants Liability
FairValueOfWarrantsLiability
13769000
CY2019 hsdt Fair Value Of Warrants Liability Exercise
FairValueOfWarrantsLiabilityExercise
35000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
384000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14113000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
341905
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
94475
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
33337
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
13939
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14855
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
99018
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
42988
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
28448
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
113558
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
57725
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y1M28D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M10D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M21D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
249.87
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
162.74
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
298.55
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
96.95
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
236.63
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.20
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
210.57
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
159.33
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
117.90
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8308000
CY2019 hsdt Stock Issued During Period Shares Stock Options Exercised On Cashless Basis
StockIssuedDuringPeriodSharesStockOptionsExercisedOnCashlessBasis
14855
CY2019 hsdt Number Of Common Stock Shares Withheld
NumberOfCommonStockSharesWithheld
13818
CY2019 hsdt Number Of Restricted Stock Units Withheld For Taxes
NumberOfRestrictedStockUnitsWithheldForTaxes
7
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2529000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4691000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
496000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
722000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
292000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
67000
CY2020Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
133000
CY2019Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
81000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
12000
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13000
CY2019Q4 hsdt Accrued Franchise Fee Current
AccruedFranchiseFeeCurrent
28000
CY2020Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
347000
CY2019Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
606000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12362000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-7980000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1768000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14130000
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-06-30
CY2017Q3 hsdt Operating Lease Option To Extend Lease Term Date
OperatingLeaseOptionToExtendLeaseTermDate
2028-01-31
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
20000
CY2017Q3 hsdt Operating Lease Rent Plus Utilities Beginning Date
OperatingLeaseRentPlusUtilitiesBeginningDate
2018-01-31
CY2017Q3 hsdt Operating Lease Annual Increase In Rental Percentage
OperatingLeaseAnnualIncreaseInRentalPercentage
0.03
CY2020Q2 hsdt Operating Lease Commencement Date
OperatingLeaseCommencementDate
2020-07-01
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9781000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14130000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9781000
CY2020 hsdt Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
-2967000
CY2019 hsdt Income Tax Reconciliation Expected Income Tax Recovery
IncomeTaxReconciliationExpectedIncomeTaxRecovery
-2054000
CY2020 hsdt Income Tax Reconciliation Change In Derivative Liability
IncomeTaxReconciliationChangeInDerivativeLiability
-1000
CY2019 hsdt Income Tax Reconciliation Change In Derivative Liability
IncomeTaxReconciliationChangeInDerivativeLiability
-2964000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
415000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
949000
CY2020 hsdt Income Tax Reconciliation Nondeductible Expense Change In Other Permanent Difference
IncomeTaxReconciliationNondeductibleExpenseChangeInOtherPermanentDifference
-21000
CY2019 hsdt Income Tax Reconciliation Nondeductible Expense Change In Other Permanent Difference
IncomeTaxReconciliationNondeductibleExpenseChangeInOtherPermanentDifference
-213000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-97000
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-99000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2671000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4381000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24576000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21318000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
882000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
679000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1616000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1496000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1099000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1293000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28173000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24786000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
85900000
CY2020 hsdt Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2033
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q1 hsdt Operating Lease Commencement Date
OperatingLeaseCommencementDate
2017-07-01
CY2017Q3 hsdt Operating Lease Commencement Date
OperatingLeaseCommencementDate
2017-07-17
CY2017Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-12-31
CY2017Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-01-16
CY2017Q1 hsdt Operating Lease Option To Extend Lease Term Year
OperatingLeaseOptionToExtendLeaseTermYear
2027
CY2020Q2 hsdt Operating Lease Option To Extend Lease Term
OperatingLeaseOptionToExtendLeaseTerm
P6M
CY2020Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
5000
CY2020Q2 hsdt Operating Lease Rent Plus Utilities Beginning Date
OperatingLeaseRentPlusUtilitiesBeginningDate
2021-01-31
CY2020Q2 hsdt Operating Lease Annual Increase In Rental Percentage
OperatingLeaseAnnualIncreaseInRentalPercentage
0.03
CY2020Q2 hsdt Decrease In Operating Lease Right Of Use Asset Partial Termination
DecreaseInOperatingLeaseRightOfUseAssetPartialTermination
400000
CY2020Q2 hsdt Decrease In Operating Lease Liability
DecreaseInOperatingLeaseLiability
400000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
107000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
224000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
253000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
246000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y18D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.151
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
32000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
95000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
91000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
637000

Files In Submission

Name View Source Status
0001564590-21-012121-index-headers.html Edgar Link pending
0001564590-21-012121-index.html Edgar Link pending
0001564590-21-012121.txt Edgar Link pending
0001564590-21-012121-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gtcqzdfzwgiu000001.jpg Edgar Link pending
gtcqzdfzwgiu000002.jpg Edgar Link pending
gtcqzdfzwgiu000003.jpg Edgar Link pending
gtcqzdfzwgiu000004.jpg Edgar Link pending
hsdt-10k_20201231.htm Edgar Link pending
hsdt-20201231.xml Edgar Link completed
hsdt-20201231.xsd Edgar Link pending
hsdt-20201231_cal.xml Edgar Link unprocessable
hsdt-20201231_def.xml Edgar Link unprocessable
hsdt-20201231_lab.xml Edgar Link unprocessable
hsdt-20201231_pre.xml Edgar Link unprocessable
hsdt-ex1024_291.htm Edgar Link pending
hsdt-ex103_292.htm Edgar Link pending
hsdt-ex211_6.htm Edgar Link pending
hsdt-ex231_11.htm Edgar Link pending
hsdt-ex311_9.htm Edgar Link pending
hsdt-ex312_8.htm Edgar Link pending
hsdt-ex321_7.htm Edgar Link pending
hsdt-ex47_10.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending